Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19825333 | 0.88 | CA12 (0.50) | CA12CA1CA2CA9MGAM | |
| SCHEMBL3496568 | 0.80 | CA12 (0.48) | CA12CA1CA2CA9MGAM | |
| SCHEMBL7483906 | 0.79 | CYP1A2 (0.44) | CA12CA1CA2CA9MGAM | |
| SCHEMBL22383552 | 0.78 | CA12 (0.47) | CA12CA1CA2CA9MGAM | |
| SCHEMBL1247150 | 0.77 | — | — | |
| SCHEMBL12589581 | 0.77 | CA12 (0.59) | CA12CA1CA2CA9MGAM | |
| SCHEMBL196815 | 0.77 | — | — | |
| SCHEMBL4059449 | 0.76 | ALDH1A1 (0.40) | CA12CA1CA2CA9MGAM | |
| Ethyl Propionate SCHEMBL27739605 | 0.76 | MGAM (0.48) | CA12CA1CA2CA9MGAM | |
| Hydrochloric Acid SCHEMBL8143027 | 0.75 | CA12 (0.57) | CA12CA1CA2CA9MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2024-10-15 | — | — | US | disclosed |
| CN-109096370-B | Polypeptide epoxy ketone compound | 圣特莱国际公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-109180780-B | Polypeptide epoxy ketone compound | 圣特莱国际公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210205464-A1 | Linker Containing Arylnitro, Antibody-Drug Conjugate Containing Linker and Use of Linker | ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| EP-3650042-A1 | DIMETHYL FUMARATE AND VACCINATION REGIMENS | Biogen MA Inc. (US) | 2020-05-13 | — | — | EP | disclosed |
| CN-103570806-B | Polypeptide epoxy ketone compound | 圣特莱国际公司 | 2020-04-07 | — | — | CN | disclosed |
| WO-2020043129-A1 | LINKER CONTAINING ARYLNITRO, ANTIBODY-DRUG CONJUGATE CONTAINING LINKER AND USE OF LINKER | 中国人民解放军军事科学院军事医学研究院 | 2020-03-05 | — | — | WO | disclosed |
| EP-3220907-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-0764645-A1 | Novel 3,4-diaryl furans and analogs thereof having use as anti-inflammatory agents | G.D. SEARLE & CO. (US) | 1997-03-26 | — | — | EP | disclosed |
| EP-0764644-A1 | Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition | G.D. SEARLE & CO. (US) | 1997-03-26 | — | — | EP | disclosed |
| EP-0759432-A1 | Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition | G.D. SEARLE & CO. (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5571810-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, COLLAGEN DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-05 | — | — | US | disclosed |
| EP-0737193-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-16 | — | — | EP | disclosed |
| EP-0679157-A1 | NOVEL 3,4-DIARYL THIOPHENES AND ANALOGS THEREOF HAVING USE AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1995018128-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994015932-A1 | NOVEL 3,4-DIARYL THIOPHENES AND ANALOGS THEREOF HAVING USE AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0593761-A1 | NEW THIOPHENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-27 | — | — | EP | disclosed |
| WO-1991019708-A1 | NEW THIOPHENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205464-A1 | Linker Containing Arylnitro, Antibody-Drug Conjugate Containing Linker and Use of Linker | BCR, FCGRT, ERBB2 | CA12 1361/4885CA1 2699/4885CA2 4189/4885 |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | CA12 1881/4885CA1 1628/4885CA2 3130/4885 |
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | BCR, FCGR2A, FCGRT | CA12 1032/4885CA1 2569/4885CA2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.